{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"vip-glp1-gut","title":"VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as a known mechanism. If your gut motility slows too much, food stays in the stomach longer. This can lead to bloating, nausea, and in some cases symptoms that resemble gastroparesis. The enteric nervous system and smooth muscle layers handle coordinated contractions. When these signals weaken or inflammation rises, repair pathways may lag behind the ongoing stress from the drug. VIP acts as a signaling molecule in the gut wall. It supports smooth muscle relaxation and fluid secretion. If your issue traces to slowed motility or enteric nerve signaling, that layer sits upstream of symptom persistence.\n\n## Why VIP might help you\n\nYou are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n\nTherefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. Step 1: GLP-1 slows emptying via direct receptor effects on the stomach. Step 2: If enteric VIP pathways are under-active or stressed, adding VIP may support the relaxation phase of peristalsis in preclinical models. Step 3: This could allow better coordination of contractions over time rather than continued suppression. The logic stays at the immune/autonomic layer where VIP receptors sit on gut neurons and immune cells.\n\n## Why GLP-1 agonists (class) matters for you\n\nDrug: GLP-1 agonists (class). What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. Therefore for you: This drug suppresses a motility signal. The suppression helps blood sugar control and appetite but trades off against normal gastric emptying speed. If your gastroparesis-like symptoms started or worsened on the drug, the tradeoff sits in the same autonomic/smooth muscle layer that VIP research targets. The metabolic support may reduce overall systemic load, yet the direct gut effect remains a known mechanism that does not promote motility repair.\n\n## How these fit together\n\nSingle-compound focus — VIP targets the immune / autonomic layer. GLP-1 agonists deliver metabolic change while adding a motility slowdown. If your profile includes both the drug load and motility symptoms, VIP sits at the repair side of the enteric signaling that the agonist can blunt. No multi-peptide stack is mapped here.\n\n## What the evidence actually shows\n\nPreclinical work shows VIP relaxes intestinal smooth muscle and supports secretion (mechanistic tier). VIP-null mice display altered glucose handling and changes in GLP-1 related pathways (preclinical). One 2024 study linked microbiome effects on small intestinal motility to VIP modulation (preclinical). No human trials of VIP for gastroparesis or GLP-1-induced gut slowing appear in the searched literature (human tier: absent). Gastroparesis reviews note delayed emptying as a core feature but do not test VIP as treatment (preclinical/mechanistic only for VIP angle).\n\n## What scientists say\n\nReviews place VIP in the glucagon/secretin family alongside GLP-1 and GLP-2. It functions as an inhibitory neurotransmitter in the gut, promoting relaxation. Animal data show VIP involvement in motility reflexes. Human data on VIP levels or supplementation in gastroparesis remain limited to indirect mentions in broader peptide physiology papers.\n\n## What people say on Reddit\n\nAnecdotal reports mention VIP in contexts of gut dysmotility and inflammatory conditions. One thread discusses VIP alongside other peptides for motility support. Separate posts describe BPC-157 experiences with gastroparesis symptoms but do not include VIP. No large volume of user reports specifically pairing VIP with GLP-1 side effects surfaced.\n\n## What people say on X\n\nPosts are mostly promotional for VIP research or list it among other peptides. One post references semaglutide side effects without linking to VIP. No detailed user outcome stories on VIP for GLP-1 gut issues appear in recent results.\n\n## What we do not know\n\nDirect human trials testing VIP administration in people with GLP-1 agonist-related gastroparesis do not exist in public literature. Dose, timing, or long-term effects on gastric emptying remain unstudied in this specific cross. Interaction strength between exogenous VIP and ongoing GLP-1 receptor activation is unknown.\n\n## Safety and limits\n\nVIP research stays at mechanistic and animal levels for this use case. Any application carries unknown risks in humans. Gastroparesis itself has established diagnostic and management paths outside peptide research. Evidence does not support claims of reversal or cure.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-glp1-gut/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP relaxes intestinal smooth muscle and supports secretion in preclinical models.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes VIP's role in gut motility relevant to gastroparesis symptoms.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human trials of VIP for gastroparesis or GLP-1-induced gut slowing were identified.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap for readers with this specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GLP-1 agonists slow gastric emptying as a direct mechanism.","section":"Why GLP-1 agonists (class) matters for you","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Explains the tradeoff for readers experiencing gut slowing on the drug.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss VIP in gut dysmotility contexts but lack specific GLP-1 gastroparesis pairings.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Separates anecdote from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.sciencedirect.com/science/article/pii/S2352345X23002114","title":"Vasoactive Intestinal Polypeptide Plays a Key Role in the Regulation of Small Intestinal Motility","quote":"small intestinal motility, but not gastric emptying or colonic motility, is regulated by the microbiome through modulation of vasoactive intestinal polypeptide (VIP)","summary":"Preclinical study linking microbiome, VIP, and intestinal motility.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:31:07.364Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"a6408787cbea58e9f9cab4755c53278063288d69a27a4016cf3b64aa019fa368"},{"id":"s2","type":"review","url":"https://gut.bmj.com/content/early/2019/09/28/gutjnl-2019-318712","title":"Gastroparesis: a turning point in understanding and treatment","quote":"Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating...","summary":"Clinical review on gastroparesis without VIP intervention data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:31:07.364Z","link_status":"http_403","quote_status":"unverified","prev":"a6408787cbea58e9f9cab4755c53278063288d69a27a4016cf3b64aa019fa368","hash":"eb20114a50b8efa03b140cb8dacf643f5b886d18209d01d85ec5123824a4801f"},{"id":"s3","type":"pubmed","url":"https://link.springer.com/article/10.1186/1471-230X-12-30","title":"Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide","quote":"GI discomfort such as nausea, bloating, abdominal pain, constipation, diarrhea or delayed gastric emptying are common features","summary":"Discusses GLP-1 effects on gastric emptying.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:31:07.364Z","link_status":"ok","quote_status":"verified","prev":"eb20114a50b8efa03b140cb8dacf643f5b886d18209d01d85ec5123824a4801f","hash":"4b9380fbdd41f58c9b2950528540fa99bc1d92453d55d2d804023f7abe7d3409"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/LAPeptidesGuide/comments/1u8cuai/bpc157_and_glp2_both_repair_the_gut_they_are/","title":"Discussion of peptides for gut issues","quote":"Individuals with chronic gut dysmotility, IBS, or inflammatory gut conditions where VIP's enteric nervous system regulatory activity addresses both motility and inflammation simultaneously","summary":"Anecdotal community mention of VIP for dysmotility.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:31:07.364Z","link_status":"ok","quote_status":"unverified","prev":"4b9380fbdd41f58c9b2950528540fa99bc1d92453d55d2d804023f7abe7d3409","hash":"69fb43dfa3c3b83e309f821123d7dd457cd6b7433bd4ac8e7516fb59b3eb27be"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:31:09.080Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers","register":"source_ledger","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as a known mechanism. If your gut motility slows too much, food stays in the stomach longer. This can lead to bloating, nausea, and in some cases symptoms that resemble gastroparesis. The enteric nervous system and smooth muscle layers handle coordinated contractions. When these signals weaken or inflammation rises, repair pathways may lag behind the ongoing stress from the drug. VIP acts as a signaling molecule in the gut wall. It supports smooth muscle relaxation and fluid secretion. If your issue traces to slowed motility or enteric nerve signaling, that layer sits upstream of symptom persistence.\n\n## Why VIP might help you\n\nYou are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n\nTherefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. Step 1: GLP-1 slows emptying via direct receptor effects on the stomach. Step 2: If enteric VIP pathways are under-active or stressed, adding VIP may support the relaxation phase of peristalsis in preclinical models. Step 3: This could allow better coordination of contractions over time rather than continued suppression. The logic stays at the immune/autonomic layer where VIP receptors sit on gut neurons and immune cells.\n\n## Why GLP-1 agonists (class) matters for you\n\nDrug: GLP-1 agonists (class). What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. Therefore for you: This drug suppresses a motility signal. The suppression helps blood sugar control and appetite but trades off against normal gastric emptying speed. If your gastroparesis-like symptoms started or worsened on the drug, the tradeoff sits in the same autonomic/smooth muscle layer that VIP research targets. The metabolic support may reduce overall systemic load, yet the direct gut effect remains a known mechanism that does not promote motility repair.\n\n## How these fit together\n\nSingle-compound focus — VIP targets the immune / autonomic layer. GLP-1 agonists deliver metabolic change while adding a motility slowdown. If your profile includes both the drug load and motility symptoms, VIP sits at the repair side of the enteric signaling that the agonist can blunt. No multi-peptide stack is mapped here.\n\n## What the evidence actually shows\n\nPreclinical work shows VIP relaxes intestinal smooth muscle and supports secretion (mechanistic tier). VIP-null mice display altered glucose handling and changes in GLP-1 related pathways (preclinical). One 2024 study linked microbiome effects on small intestinal motility to VIP modulation (preclinical). No human trials of VIP for gastroparesis or GLP-1-induced gut slowing appear in the searched literature (human tier: absent). Gastroparesis reviews note delayed emptying as a core feature but do not test VIP as treatment (preclinical/mechanistic only for VIP angle).\n\n## What scientists say\n\nReviews place VIP in the glucagon/secretin family alongside GLP-1 and GLP-2. It functions as an inhibitory neurotransmitter in the gut, promoting relaxation. Animal data show VIP involvement in motility reflexes. Human data on VIP levels or supplementation in gastroparesis remain limited to indirect mentions in broader peptide physiology papers.\n\n## What people say on Reddit\n\nAnecdotal reports mention VIP in contexts of gut dysmotility and inflammatory conditions. One thread discusses VIP alongside other peptides for motility support. Separate posts describe BPC-157 experiences with gastroparesis symptoms but do not include VIP. No large volume of user reports specifically pairing VIP with GLP-1 side effects surfaced.\n\n## What people say on X\n\nPosts are mostly promotional for VIP research or list it among other peptides. One post references semaglutide side effects without linking to VIP. No detailed user outcome stories on VIP for GLP-1 gut issues appear in recent results.\n\n## What we do not know\n\nDirect human trials testing VIP administration in people with GLP-1 agonist-related gastroparesis do not exist in public literature. Dose, timing, or long-term effects on gastric emptying remain unstudied in this specific cross. Interaction strength between exogenous VIP and ongoing GLP-1 receptor activation is unknown.\n\n## Safety and limits\n\nVIP research stays at mechanistic and animal levels for this use case. Any application carries unknown risks in humans. Gastroparesis itself has established diagnostic and management paths outside peptide research. Evidence does not support claims of reversal or cure.","claims":[{"id":"c1","text":"VIP relaxes intestinal smooth muscle and supports secretion in preclinical models.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes VIP's role in gut motility relevant to gastroparesis symptoms.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human trials of VIP for gastroparesis or GLP-1-induced gut slowing were identified.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap for readers with this specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GLP-1 agonists slow gastric emptying as a direct mechanism.","section":"Why GLP-1 agonists (class) matters for you","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Explains the tradeoff for readers experiencing gut slowing on the drug.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss VIP in gut dysmotility contexts but lack specific GLP-1 gastroparesis pairings.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Separates anecdote from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.sciencedirect.com/science/article/pii/S2352345X23002114","title":"Vasoactive Intestinal Polypeptide Plays a Key Role in the Regulation of Small Intestinal Motility","quote":"small intestinal motility, but not gastric emptying or colonic motility, is regulated by the microbiome through modulation of vasoactive intestinal polypeptide (VIP)","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"review","url":"https://gut.bmj.com/content/early/2019/09/28/gutjnl-2019-318712","title":"Gastroparesis: a turning point in understanding and treatment","quote":"Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating...","link_status":"http_403","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://link.springer.com/article/10.1186/1471-230X-12-30","title":"Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide","quote":"GI discomfort such as nausea, bloating, abdominal pain, constipation, diarrhea or delayed gastric emptying are common features","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/LAPeptidesGuide/comments/1u8cuai/bpc157_and_glp2_both_repair_the_gut_they_are/","title":"Discussion of peptides for gut issues","quote":"Individuals with chronic gut dysmotility, IBS, or inflammatory gut conditions where VIP's enteric nervous system regulatory activity addresses both motility and inflammation simultaneously","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":16064,"tokens_out":3003,"cost":0.0275875,"prev_hash":"genesis","hash":"3ccdea2de78f54bdd755d103fffbd42f08bc872b0c0beb6d10aba31609f42bc5"}],"provenance":[{"ts":"2026-06-29T22:31:09.080Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Glp1 Gut\nSlug: vip-glp1-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"GLP-1 gut damage / gastroparesis\",\"condition_key\":\"glp1-gut-damage\",\"primary_peptide\":\"vip\",\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have GLP-1 gut damage / gastroparesis\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load","response":"{\n  \"slug\": \"vip-glp1-gut\",\n  \"title\": \"VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers\",\n  \"body\": \"## What's breaking down if you have GLP-1 gut damage / gastroparesis\\n\\nGLP-1 agonists slow gastric emptying as a known mechanism. If your gut motility slows too much, food stays in the stomach longer. This can lead to bloating, nausea, and in some cases symptoms that resemble gastroparesis. The enteric nervous system and smooth muscle layers handle coordinated contractions. When these signals weaken or inflammation rises, repair pathways may lag behind the ongoing stress from the drug. VIP acts as a signaling molecule in the gut wall. It supports smooth muscle relaxation and fluid secretion. If your issue traces to slowed motility or enteric nerve signaling, that layer sits upstream of symptom persistence.\\n\\n## Why VIP might help you\\n\\nYou are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\\n\\nTherefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. Step 1: GLP-1 slows emptying via direct receptor effects on the stomach. Step 2: If enteric VIP pathways are under-active or stressed, adding VIP may support the relaxation phase of peristalsis in preclinical models. Step 3: This could allow better coordination of contractions over time rather than continued suppression. The logic stays at the immune/autonomic layer where VIP receptors sit on gut neurons and immune cells.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nDrug: GLP-1 agonists (class). What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. Therefore for you: This drug suppresses a motility signal. The suppression helps blood sugar control and appetite but trades off against normal gastric emptying speed. If your gastroparesis-like symptoms started or worsened on the drug, the tradeoff sits in the sam","tokens_in":16064,"tokens_out":3003,"cost":0,"prev":"genesis","hash":"60d85b8fb55b5eb0e777bd4f5b7333312bc4ca975375fa5993795f8e1453a8a9"},{"ts":"2026-07-17T02:43:24.048Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-glp1-gut","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"60d85b8fb55b5eb0e777bd4f5b7333312bc4ca975375fa5993795f8e1453a8a9","hash":"da9c46b13888f53aa97a24eff52365f641fa04bde4c488bf29c5a37073cd8a34"}],"energy":{"passes":2,"tokens_in":16064,"tokens_out":3003,"tokens_total":19067,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"da9c46b13888f53aa97a24eff52365f641fa04bde4c488bf29c5a37073cd8a34"},"posted_at":"2026-06-29T21:33:50.171Z","created_at":"2026-06-29T21:33:50.171Z","updated_at":"2026-07-17T02:43:24.048Z","machine":{"shape":"article.machine/v1","slug":"vip-glp1-gut","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-glp1-gut","json":"https://miscsubjects.com/api/articles/vip-glp1-gut","bundle":"https://miscsubjects.com/api/articles/vip-glp1-gut/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-glp1-gut/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-glp1-gut","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-glp1-gut\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-glp1-gut\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-glp1-gut/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-glp1-gut\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-glp1-gut | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-glp1-gut","json":"/api/articles/vip-glp1-gut","markdown":"/api/articles/vip-glp1-gut/bundle?format=markdown","skill":"/api/articles/vip-glp1-gut/skill","topology":"/api/articles/vip-glp1-gut/topology","versions":"/api/articles/vip-glp1-gut/revisions","invocations":"/api/articles/vip-glp1-gut/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-glp1-gut","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"84a4acf76b7f934df21bd5c485ebc82d808b7a99798752053e212e71b37ce9b3","object":{"object_type":"article-object","identity":{"id":"article:vip-glp1-gut","slug":"vip-glp1-gut","title":"VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/vip-glp1-gut","role":"explain","audience":"human"},"skill":{"route":"/api/articles/vip-glp1-gut/skill","role":"direct behavior","audience":"model","content":"---\nname: vip-glp1-gut\ndescription: Apply the VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers\n\nThis Skill is the behavioral expression of [the canonical article](/a/vip-glp1-gut). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/vip-glp1-gut.\n- Read claims and relationships at /api/articles/vip-glp1-gut/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have GLP-1 gut damage / gastroparesis GLP-1 agonists slow gastric emptying as a known mechanism. If your gut motility slows too much, food stays in the stomach longer. This can lead to bloating, nausea, and in so\n\n## Representations\n\n- Human: /a/vip-glp1-gut\n- JSON: /api/articles/vip-glp1-gut\n- Relationships: /api/articles/vip-glp1-gut/topology\n- History: /api/articles/vip-glp1-gut/revisions\n"},"json":{"route":"/api/articles/vip-glp1-gut","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/vip-glp1-gut/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","vip","glp1","gut"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/vip-glp1-gut/invocations?status=success","failure_events":"/api/articles/vip-glp1-gut/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"vip-glp1-gut","title":"VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as a known mechanism. If your gut motility slows too much, food stays in the stomach longer. This can lead to bloating, nausea, and in some cases symptoms that resemble gastroparesis. The enteric nervous system and smooth muscle layers handle coordinated contractions. When these signals weaken or inflammation rises, repair pathways may lag behind the ongoing stress from the drug. VIP acts as a signaling molecule in the gut wall. It supports smooth muscle relaxation and fluid secretion. If your issue traces to slowed motility or enteric nerve signaling, that layer sits upstream of symptom persistence.\n\n## Why VIP might help you\n\nYou are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n\nTherefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. Step 1: GLP-1 slows emptying via direct receptor effects on the stomach. Step 2: If enteric VIP pathways are under-active or stressed, adding VIP may support the relaxation phase of peristalsis in preclinical models. Step 3: This could allow better coordination of contractions over time rather than continued suppression. The logic stays at the immune/autonomic layer where VIP receptors sit on gut neurons and immune cells.\n\n## Why GLP-1 agonists (class) matters for you\n\nDrug: GLP-1 agonists (class). What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. Therefore for you: This drug suppresses a motility signal. The suppression helps blood sugar control and appetite but trades off against normal gastric emptying speed. If your gastroparesis-like symptoms started or worsened on the drug, the tradeoff sits in the same autonomic/smooth muscle layer that VIP research targets. The metabolic support may reduce overall systemic load, yet the direct gut effect remains a known mechanism that does not promote motility repair.\n\n## How these fit together\n\nSingle-compound focus — VIP targets the immune / autonomic layer. GLP-1 agonists deliver metabolic change while adding a motility slowdown. If your profile includes both the drug load and motility symptoms, VIP sits at the repair side of the enteric signaling that the agonist can blunt. No multi-peptide stack is mapped here.\n\n## What the evidence actually shows\n\nPreclinical work shows VIP relaxes intestinal smooth muscle and supports secretion (mechanistic tier). VIP-null mice display altered glucose handling and changes in GLP-1 related pathways (preclinical). One 2024 study linked microbiome effects on small intestinal motility to VIP modulation (preclinical). No human trials of VIP for gastroparesis or GLP-1-induced gut slowing appear in the searched literature (human tier: absent). Gastroparesis reviews note delayed emptying as a core feature but do not test VIP as treatment (preclinical/mechanistic only for VIP angle).\n\n## What scientists say\n\nReviews place VIP in the glucagon/secretin family alongside GLP-1 and GLP-2. It functions as an inhibitory neurotransmitter in the gut, promoting relaxation. Animal data show VIP involvement in motility reflexes. Human data on VIP levels or supplementation in gastroparesis remain limited to indirect mentions in broader peptide physiology papers.\n\n## What people say on Reddit\n\nAnecdotal reports mention VIP in contexts of gut dysmotility and inflammatory conditions. One thread discusses VIP alongside other peptides for motility support. Separate posts describe BPC-157 experiences with gastroparesis symptoms but do not include VIP. No large volume of user reports specifically pairing VIP with GLP-1 side effects surfaced.\n\n## What people say on X\n\nPosts are mostly promotional for VIP research or list it among other peptides. One post references semaglutide side effects without linking to VIP. No detailed user outcome stories on VIP for GLP-1 gut issues appear in recent results.\n\n## What we do not know\n\nDirect human trials testing VIP administration in people with GLP-1 agonist-related gastroparesis do not exist in public literature. Dose, timing, or long-term effects on gastric emptying remain unstudied in this specific cross. Interaction strength between exogenous VIP and ongoing GLP-1 receptor activation is unknown.\n\n## Safety and limits\n\nVIP research stays at mechanistic and animal levels for this use case. Any application carries unknown risks in humans. Gastroparesis itself has established diagnostic and management paths outside peptide research. Evidence does not support claims of reversal or cure.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-glp1-gut/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP relaxes intestinal smooth muscle and supports secretion in preclinical models.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes VIP's role in gut motility relevant to gastroparesis symptoms.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human trials of VIP for gastroparesis or GLP-1-induced gut slowing were identified.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap for readers with this specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GLP-1 agonists slow gastric emptying as a direct mechanism.","section":"Why GLP-1 agonists (class) matters for you","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Explains the tradeoff for readers experiencing gut slowing on the drug.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss VIP in gut dysmotility contexts but lack specific GLP-1 gastroparesis pairings.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Separates anecdote from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.sciencedirect.com/science/article/pii/S2352345X23002114","title":"Vasoactive Intestinal Polypeptide Plays a Key Role in the Regulation of Small Intestinal Motility","quote":"small intestinal motility, but not gastric emptying or colonic motility, is regulated by the microbiome through modulation of vasoactive intestinal polypeptide (VIP)","summary":"Preclinical study linking microbiome, VIP, and intestinal motility.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:31:07.364Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"a6408787cbea58e9f9cab4755c53278063288d69a27a4016cf3b64aa019fa368"},{"id":"s2","type":"review","url":"https://gut.bmj.com/content/early/2019/09/28/gutjnl-2019-318712","title":"Gastroparesis: a turning point in understanding and treatment","quote":"Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating...","summary":"Clinical review on gastroparesis without VIP intervention data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:31:07.364Z","link_status":"http_403","quote_status":"unverified","prev":"a6408787cbea58e9f9cab4755c53278063288d69a27a4016cf3b64aa019fa368","hash":"eb20114a50b8efa03b140cb8dacf643f5b886d18209d01d85ec5123824a4801f"},{"id":"s3","type":"pubmed","url":"https://link.springer.com/article/10.1186/1471-230X-12-30","title":"Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide","quote":"GI discomfort such as nausea, bloating, abdominal pain, constipation, diarrhea or delayed gastric emptying are common features","summary":"Discusses GLP-1 effects on gastric emptying.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:31:07.364Z","link_status":"ok","quote_status":"verified","prev":"eb20114a50b8efa03b140cb8dacf643f5b886d18209d01d85ec5123824a4801f","hash":"4b9380fbdd41f58c9b2950528540fa99bc1d92453d55d2d804023f7abe7d3409"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/LAPeptidesGuide/comments/1u8cuai/bpc157_and_glp2_both_repair_the_gut_they_are/","title":"Discussion of peptides for gut issues","quote":"Individuals with chronic gut dysmotility, IBS, or inflammatory gut conditions where VIP's enteric nervous system regulatory activity addresses both motility and inflammation simultaneously","summary":"Anecdotal community mention of VIP for dysmotility.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:31:07.364Z","link_status":"ok","quote_status":"unverified","prev":"4b9380fbdd41f58c9b2950528540fa99bc1d92453d55d2d804023f7abe7d3409","hash":"69fb43dfa3c3b83e309f821123d7dd457cd6b7433bd4ac8e7516fb59b3eb27be"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:31:09.080Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers","register":"source_ledger","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as a known mechanism. If your gut motility slows too much, food stays in the stomach longer. This can lead to bloating, nausea, and in some cases symptoms that resemble gastroparesis. The enteric nervous system and smooth muscle layers handle coordinated contractions. When these signals weaken or inflammation rises, repair pathways may lag behind the ongoing stress from the drug. VIP acts as a signaling molecule in the gut wall. It supports smooth muscle relaxation and fluid secretion. If your issue traces to slowed motility or enteric nerve signaling, that layer sits upstream of symptom persistence.\n\n## Why VIP might help you\n\nYou are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n\nTherefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. Step 1: GLP-1 slows emptying via direct receptor effects on the stomach. Step 2: If enteric VIP pathways are under-active or stressed, adding VIP may support the relaxation phase of peristalsis in preclinical models. Step 3: This could allow better coordination of contractions over time rather than continued suppression. The logic stays at the immune/autonomic layer where VIP receptors sit on gut neurons and immune cells.\n\n## Why GLP-1 agonists (class) matters for you\n\nDrug: GLP-1 agonists (class). What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. Therefore for you: This drug suppresses a motility signal. The suppression helps blood sugar control and appetite but trades off against normal gastric emptying speed. If your gastroparesis-like symptoms started or worsened on the drug, the tradeoff sits in the same autonomic/smooth muscle layer that VIP research targets. The metabolic support may reduce overall systemic load, yet the direct gut effect remains a known mechanism that does not promote motility repair.\n\n## How these fit together\n\nSingle-compound focus — VIP targets the immune / autonomic layer. GLP-1 agonists deliver metabolic change while adding a motility slowdown. If your profile includes both the drug load and motility symptoms, VIP sits at the repair side of the enteric signaling that the agonist can blunt. No multi-peptide stack is mapped here.\n\n## What the evidence actually shows\n\nPreclinical work shows VIP relaxes intestinal smooth muscle and supports secretion (mechanistic tier). VIP-null mice display altered glucose handling and changes in GLP-1 related pathways (preclinical). One 2024 study linked microbiome effects on small intestinal motility to VIP modulation (preclinical). No human trials of VIP for gastroparesis or GLP-1-induced gut slowing appear in the searched literature (human tier: absent). Gastroparesis reviews note delayed emptying as a core feature but do not test VIP as treatment (preclinical/mechanistic only for VIP angle).\n\n## What scientists say\n\nReviews place VIP in the glucagon/secretin family alongside GLP-1 and GLP-2. It functions as an inhibitory neurotransmitter in the gut, promoting relaxation. Animal data show VIP involvement in motility reflexes. Human data on VIP levels or supplementation in gastroparesis remain limited to indirect mentions in broader peptide physiology papers.\n\n## What people say on Reddit\n\nAnecdotal reports mention VIP in contexts of gut dysmotility and inflammatory conditions. One thread discusses VIP alongside other peptides for motility support. Separate posts describe BPC-157 experiences with gastroparesis symptoms but do not include VIP. No large volume of user reports specifically pairing VIP with GLP-1 side effects surfaced.\n\n## What people say on X\n\nPosts are mostly promotional for VIP research or list it among other peptides. One post references semaglutide side effects without linking to VIP. No detailed user outcome stories on VIP for GLP-1 gut issues appear in recent results.\n\n## What we do not know\n\nDirect human trials testing VIP administration in people with GLP-1 agonist-related gastroparesis do not exist in public literature. Dose, timing, or long-term effects on gastric emptying remain unstudied in this specific cross. Interaction strength between exogenous VIP and ongoing GLP-1 receptor activation is unknown.\n\n## Safety and limits\n\nVIP research stays at mechanistic and animal levels for this use case. Any application carries unknown risks in humans. Gastroparesis itself has established diagnostic and management paths outside peptide research. Evidence does not support claims of reversal or cure.","claims":[{"id":"c1","text":"VIP relaxes intestinal smooth muscle and supports secretion in preclinical models.","section":"What the evidence actually shows","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes VIP's role in gut motility relevant to gastroparesis symptoms.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human trials of VIP for gastroparesis or GLP-1-induced gut slowing were identified.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap for readers with this specific cross.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GLP-1 agonists slow gastric emptying as a direct mechanism.","section":"Why GLP-1 agonists (class) matters for you","tier":"mechanistic","source_ids":["s3"],"source_status":"sourced","why_material":"Explains the tradeoff for readers experiencing gut slowing on the drug.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss VIP in gut dysmotility contexts but lack specific GLP-1 gastroparesis pairings.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Separates anecdote from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:08.657Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.sciencedirect.com/science/article/pii/S2352345X23002114","title":"Vasoactive Intestinal Polypeptide Plays a Key Role in the Regulation of Small Intestinal Motility","quote":"small intestinal motility, but not gastric emptying or colonic motility, is regulated by the microbiome through modulation of vasoactive intestinal polypeptide (VIP)","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"review","url":"https://gut.bmj.com/content/early/2019/09/28/gutjnl-2019-318712","title":"Gastroparesis: a turning point in understanding and treatment","quote":"Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating...","link_status":"http_403","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://link.springer.com/article/10.1186/1471-230X-12-30","title":"Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide","quote":"GI discomfort such as nausea, bloating, abdominal pain, constipation, diarrhea or delayed gastric emptying are common features","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/LAPeptidesGuide/comments/1u8cuai/bpc157_and_glp2_both_repair_the_gut_they_are/","title":"Discussion of peptides for gut issues","quote":"Individuals with chronic gut dysmotility, IBS, or inflammatory gut conditions where VIP's enteric nervous system regulatory activity addresses both motility and inflammation simultaneously","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":16064,"tokens_out":3003,"cost":0.0275875,"prev_hash":"genesis","hash":"3ccdea2de78f54bdd755d103fffbd42f08bc872b0c0beb6d10aba31609f42bc5"}],"provenance":[{"ts":"2026-06-29T22:31:09.080Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Glp1 Gut\nSlug: vip-glp1-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"GLP-1 gut damage / gastroparesis\",\"condition_key\":\"glp1-gut-damage\",\"primary_peptide\":\"vip\",\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have GLP-1 gut damage / gastroparesis\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load","response":"{\n  \"slug\": \"vip-glp1-gut\",\n  \"title\": \"VIP Peptide and GLP-1 Agonist Gut Effects: Evidence on Motility and Repair Layers\",\n  \"body\": \"## What's breaking down if you have GLP-1 gut damage / gastroparesis\\n\\nGLP-1 agonists slow gastric emptying as a known mechanism. If your gut motility slows too much, food stays in the stomach longer. This can lead to bloating, nausea, and in some cases symptoms that resemble gastroparesis. The enteric nervous system and smooth muscle layers handle coordinated contractions. When these signals weaken or inflammation rises, repair pathways may lag behind the ongoing stress from the drug. VIP acts as a signaling molecule in the gut wall. It supports smooth muscle relaxation and fluid secretion. If your issue traces to slowed motility or enteric nerve signaling, that layer sits upstream of symptom persistence.\\n\\n## Why VIP might help you\\n\\nYou are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\\n\\nTherefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. Step 1: GLP-1 slows emptying via direct receptor effects on the stomach. Step 2: If enteric VIP pathways are under-active or stressed, adding VIP may support the relaxation phase of peristalsis in preclinical models. Step 3: This could allow better coordination of contractions over time rather than continued suppression. The logic stays at the immune/autonomic layer where VIP receptors sit on gut neurons and immune cells.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\nDrug: GLP-1 agonists (class). What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. Therefore for you: This drug suppresses a motility signal. The suppression helps blood sugar control and appetite but trades off against normal gastric emptying speed. If your gastroparesis-like symptoms started or worsened on the drug, the tradeoff sits in the sam","tokens_in":16064,"tokens_out":3003,"cost":0,"prev":"genesis","hash":"60d85b8fb55b5eb0e777bd4f5b7333312bc4ca975375fa5993795f8e1453a8a9"},{"ts":"2026-07-17T02:43:24.048Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-glp1-gut","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"60d85b8fb55b5eb0e777bd4f5b7333312bc4ca975375fa5993795f8e1453a8a9","hash":"da9c46b13888f53aa97a24eff52365f641fa04bde4c488bf29c5a37073cd8a34"}],"energy":{"passes":2,"tokens_in":16064,"tokens_out":3003,"tokens_total":19067,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"da9c46b13888f53aa97a24eff52365f641fa04bde4c488bf29c5a37073cd8a34"},"posted_at":"2026-06-29T21:33:50.171Z","created_at":"2026-06-29T21:33:50.171Z","updated_at":"2026-07-17T02:43:24.048Z","machine":{"shape":"article.machine/v1","slug":"vip-glp1-gut","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-glp1-gut","json":"https://miscsubjects.com/api/articles/vip-glp1-gut","bundle":"https://miscsubjects.com/api/articles/vip-glp1-gut/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-glp1-gut/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-glp1-gut","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-glp1-gut\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-glp1-gut\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-glp1-gut/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-glp1-gut\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-glp1-gut | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-glp1-gut","json":"/api/articles/vip-glp1-gut","markdown":"/api/articles/vip-glp1-gut/bundle?format=markdown","skill":"/api/articles/vip-glp1-gut/skill","topology":"/api/articles/vip-glp1-gut/topology","versions":"/api/articles/vip-glp1-gut/revisions","invocations":"/api/articles/vip-glp1-gut/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-glp1-gut","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"84a4acf76b7f934df21bd5c485ebc82d808b7a99798752053e212e71b37ce9b3"}}}